Operating Segments (Tables)

6 Months Ended

12 Months Ended

Jun. 30, 2015

Dec. 31, 2014

Operating Segments [Abstract]

Summary of segmental information

	Three Months Ended  June 30,
	2015			2014
Contract/Grant Revenue
Vaccines/BioDefense	$	1,099,827		$	1,321,385
BioTherapeutics		—			96,863
Total	$	1,099,827		$	1,418,248
Income (Loss) from Operations
Vaccines/BioDefense	$	302,531		$	264,810
BioTherapeutics		(1,383,167	)		(650,477	)
Corporate		(954,115	)		(1,310,164	)
Total	$	(2,034,751	)	$	(1,695,831	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	9,941		$	9,809
BioTherapeutics		49,866			49,072
Corporate		1,924			1,526
Total	$	61,731		$	60,407
Other Income / (Expense), Net
Corporate	$	(1,942,943	)	$	747,314
Share-Based Compensation
Vaccines/BioDefense	$	19,344		$	10,450
BioTherapeutics		30,179			33,135
Corporate		87,640			77,672
Total	$	137,163		$	121,257

	Six Months Ended  June 30,
	2015			2014
Contract/Grant Revenue
Vaccines/BioDefense	$	1,902,141		$	2,198,430
BioTherapeutics		13,972			130,415
Total	$	1,916,113		$	2,328,845
Income (Loss) from Operations
Vaccines/BioDefense	$	387,212		$	404,214
BioTherapeutics		(2,148,043	)		(1,686,068	)
Corporate		(1,832,187	)		(2,003,886	)
Total	$	(3,593,018	)	$	(3,285,740	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	19,727		$	19,744
BioTherapeutics		98,240			99,011
Corporate		3,690			3,739
Total	$	121,657		$	122,494
Other Income / (Expense), Net
Corporate	$	(4,953,998	)	$	(994,485	)
Share-Based Compensation
Vaccines/BioDefense	$	43,936		$	20,900
BioTherapeutics		59,435			109,256
Corporate		175,817			167,763
Total	$	279,188		$	297,919

	As of  June 30,  2015		As of  December 31,  2014
Identifiable Assets
Vaccines/BioDefense	$945,991		$1,025,220
BioTherapeutics		113,916		204,308
Corporate		4,306,282		5,724,720
Total	$	5,366,189	$	6,954,248

	For the Years Ended December 31,
	2014			2013
Revenues
Vaccines/BioDefense	$	6,756,388		$	3,003,822
BioTherapeutics		286,628			220,330
Total	$	7,043,016		$	3,224,152
Income (loss) from Operations
Vaccines/BioDefense	$	807,164		$	(1,666,130	)
BioTherapeutics		(7,674,381	)		(3,069,998	)
Corporate		(3,894,132	)		(2,420,414	)
Total	$	(10,761,349	)	$	(7,156,542	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	39,625		$	37,981
BioTherapeutics		199,196			190,033
Corporate		6,966			2,057
Total	$	245,787		$	230,071
Interest Income
Corporate	$	1,310		$	1,960
Stock-Based Compensation
Vaccines/BioDefense	$	114,920		$	80,432
BioTherapeutics		193,926			250,431
Corporate		411,304			472,197
Total	$	720,150		$	803,060

	As of December 31,
	2014		2013
Identifiable Assets
Vaccines/BioDefense	$	1,025,220	$	1,870,414
BioTherapeutics		204,308		386,721
Corporate		5,724,720		6,008,320
Total	$	6,954,248	$	8,265,455